Table 1.
Baseline characteristics of the random sub-cohort of 500 psoriasis patients and prevalence cohort of 1905 patients
| Random sub-cohort (n=500) | Prevalence cohort (n=1905) | |
|---|---|---|
| Age, years, mean (±SD) | 42.8 (±16.8) | 48.8 (±17.5) |
|
| ||
| Men, % | 255 (51%) | 921 (48%) |
|
| ||
| Psoriasis characteristics at cohort entry, no (%) | ||
|
| ||
| Prevalent patients | -- | 1245 (65%) |
|
| ||
| Psoriatic arthritis* | 12 (2.4%) | 96 (5%) |
|
| ||
| Plaque psoriasis | 380 (76%) | |
| Other | 105 (21%) | |
| Unknown | 15 (3%) | |
|
| ||
| Nail involvement | 69 (14%) | |
|
| ||
| Number of affected sites | 1.9 (±1.1) | |
|
| ||
| Location | ||
| Scalp | 214 (46%) | |
| Trunk | 117 (25%) | |
| Intergluteal perianal | 47 (10%) | |
|
| ||
| Cardiovascular risk factors, no (%) | ||
|
| ||
| Obesity | 117 (25%) | 476 (25%) |
|
| ||
| Body Mass index, kg/m2, mean (±SD) | 27.2 (±6.0) | 28.3 (±6.4) |
| ≤20.0 | 28 (6%) | 77 (5%) |
| 20.1–24.9 | 161 (35%) | 408 (28%) |
| 25–29.9 | 160 (34%) | 471 (33%) |
| 30.0–34.9 | 66 (14%) | 269 (19%) |
| ≥35 | 51 (11%) | 207 (14%) |
|
| ||
| Dyslipidemia | 213 (43%) | 630 (33%) |
|
| ||
| Serum cholesterol, mg/dl, mean (±SD) | ||
| Total cholesterol | 213.4 (±49) | 202 (±42) |
| High-density lipoprotein cholesterol | 47.1 (±18.2) | 51 (±15) |
| Low-density lipoprotein cholesterol | 129.5 (±35.9) | 118 (±36) |
| Triglycerides | 159 (±201.2) | 166 (±109) |
|
| ||
| Hypertension | 159 (32%) | 642 (34%) |
|
| ||
| Blood pressure, mmHg, mean (±SD) | ||
| Systolic | 128.7 (±20.0) | 128 (±20) |
| Diastolic | 77.9 (±11.9) | 76 (±11) |
|
| ||
| Diabetes mellitus | 28 (6%) | 257 (13%) |
|
| ||
| Smoking status | ||
| Current smoker | 179 (37%) | |
| Former/ever smoker | 134 (27%) | |
| Never smoked | 177 (36%) | |
|
| ||
| Alcohol use | 83 (17%) | |
|
| ||
| History of cardiovascular disease | 23 (5%) | 221 (12%) |
| Heart failure | 8 (2%) | 39 (2%) |
| Stroke | 3 (0.6%) | 136 (7%) |
| MI or revascularization | 13 (3%) | 86 (5%) |
|
| ||
| History of psoriasis treatment at baseline | ||
|
| ||
| Phototherapy | -- | 21 (1%) |
| Any systemic treatment | 82 (4%) | |
*
Including patients who developed PSA during follow-up, there were a total of 30 PSA patients in the random sub-cohort and total 191 in the prevalence cohort over the entire follow-up period.